Paloma Giangrande
Company: Orbital Therapeutics
Job title: Senior Vice President - Discovery & Translational Biology
Bio:
Dr. Paloma Giangrande is an internationally recognized expert in nucleic acid therapeutics and delivery. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver, significantly expanding the therapeutic potential of RNA interference. She has held key leadership roles in renowned biotechnology companies, including as Director of Rare Diseases at Moderna, where she spearheaded mRNA therapeutic programs for rare genetic diseases; as Vice President of Platform Biology at Wave Life Sciences, where she led the groundbreaking RNA Editing program to a first-in-human stage, and as Chief Technology Officer at Eleven Therapeutics, where she drove the strategic direction for the company’s core xRNA technologies and platforms. Her strategic leadership at prestigious institutions underscores her commitment to advancing innovative RNA-based treatments.
Seminars:
Conjugation Chemistry, Targeted Delivery Beyond the Liver and the Surprising Breakthroughs of 2025: A Fireside Chat with Industry Innovators 1:30 pm
Join leading experts in oligonucleotide delivery for a forward-looking exploration of the chemistries and technologies driving next-generation RNA therapeutics. Opening with a focused, high-impact overview of state-of-the-art conjugation strategies across oligo modalities and expanding the conversation to discuss the broader evolution of delivery, from decades of liver-centric limitations to the emerging wave of extra-hepatic targeting. Together,…Read more
day: Conference Day Two
Leveraging Delivery Approaches to Translate Oligonucleotide-Based Therapies for Different Indications 9:05 am
The success of oligonucleotide therapeutics hinges not only on target selection and chemistry but also on delivery strategies that can unlock extrahepatic targets and expand the reach of these modalities. While conjugate-based approaches have driven remarkable progress in hepatocyte delivery, new indications, from neuromuscular diseases to oncology, demand innovative delivery solutions to overcome biological barriers,…Read more
day: Pre-Conference Workshop Day
Chair’s Opening Remarks 8:55 am
day: Conference Day Two
Chair’s Closing Remarks 3:30 pm
day: Conference Day Two